"Unilife has granted Sanofi non-exclusive access to its wearable...

"Unilife has granted Sanofi non-exclusive access to its wearable injector technology during the agreement. Unilife maintains the right to enter into supply agreements with other pharmaceutical companies for the use of its wearable injectors, so long as Sanofi's non-exclusive access is preserved. Sanofi also has the option to extend the agreement for additional periods. In addition to an upfront payment and device sales, Unilife anticipates it will receive approximately $50 million from customization programs relating to Sanofi molecules and indications. Additional revenue is also expected from customization programs conducted under joint collaborations with Sanofi partners. Unilife will begin to generate revenue from Sanofi this fiscal year from an upfront payment, customization programs and initial commercial sales of the devices to Sanofi."

From my previous posts I've made mention of the interchangeable components that can be customised to suit Customers.

Now its becoming imo, somewhat of a mystery, these upfront payments for the customisation programs ie The customisation programs cant go on forever and what does the 50 million cover for ##### sake. Is there or has there ever been any updates specifily related to the customisation programs, in this case Sanofi?

UNS signs contracts/deals with each customer for the startup customised products which each Company fronts supposed Cash for eg Sanofi $50m, then UNS reports losses of ten plus million per qtr noted as Research and Developement?

Somethings not right here. Its out of whack. imo If the customer fronts the costs and Unilife Products are finished as interchangeable components. The customisation should be covered by the customer as I'm led to believe from Releases about the Deals?
Perhaps they have millions and millions of product in storage. That is not R&D!

Anyone, Please explain as I am a new holder.!

Md